Class-level aggregation obscures clinically relevant heterogeneity in anti-amyloid antibody trials: comments on a Cochrane review by individual members of the EADC

Kristian Steen Frederiksen; Mercè Boada; Lutz Frölich; Milica Kramberger; Nikolaos Scarmeas; Everard Vijverberg; Pieter Jelle Visser; Gunhild Waldemar; Eric Westman; Henrik Zetterberg; Sebastiaan Engelborghs; Frank Jessen

doi:10.1016/j.tjpad.2026.100598

Class-level aggregation obscures clinically relevant heterogeneity in anti-amyloid antibody trials: comments on a Cochrane review by individual members of the EADC

Kristian Steen Frederiksen^*
, Mercè Boada
, Lutz Frölich
, Milica Kramberger
, Nikolaos Scarmeas
, Everard Vijverberg
, Pieter Jelle Visser
, Gunhild Waldemar
, Eric Westman
, Henrik Zetterberg
, Sebastiaan Engelborghs
, Frank Jessen

^*Corresponding author for this work

University of Copenhagen
UIC Barcelona
Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas
Heidelberg University
University Medical Centre Ljubljana Department of Neurology
Karolinska Institutet
National and Kapodistrian University of Athens
Columbia University
Vrije Universiteit Amsterdam
Maastricht University
University of Gothenburg
Sahlgrenska University Hospital
University College London
University of Wisconsin-Madison
Indian Institute of Science Bangalore
Vrije Universiteit Brussel
University of Cologne
German Center for Neurodegenerative Diseases

Research output: Contribution to journal › Article › Academic › peer-review

5 Downloads (Pure)

Original language	English
Article number	100598
Journal	Journal of Prevention of Alzheimer's Disease
Volume	13
Issue number	7
DOIs	https://doi.org/10.1016/j.tjpad.2026.100598
Publication status	Published - 1 Aug 2026

Keywords

Alzheimer's disease
Anti-amyloid
Monocloncal antibodies

Access to Document

10.1016/j.tjpad.2026.100598

Class-level-aggregation-obscures-clinically-relevant-heterogeneity-in-anti-amyloid-antibody-trials.pdfFinal published version, 400 KBLicence: CC BY

Cite this

Frederiksen, K. S., Boada, M., Frölich, L., Kramberger, M., Scarmeas, N., Vijverberg, E., Visser, P. J., Waldemar, G., Westman, E., Zetterberg, H., Engelborghs, S., & Jessen, F. (2026). Class-level aggregation obscures clinically relevant heterogeneity in anti-amyloid antibody trials: comments on a Cochrane review by individual members of the EADC. Journal of Prevention of Alzheimer's Disease, 13(7), Article 100598. https://doi.org/10.1016/j.tjpad.2026.100598

@article{9fdc2861288d49bfb4d39fcec1cfbc23,

title = "Class-level aggregation obscures clinically relevant heterogeneity in anti-amyloid antibody trials: comments on a Cochrane review by individual members of the EADC",

keywords = "Alzheimer's disease, Anti-amyloid, Monocloncal antibodies",

author = "Frederiksen, \{Kristian Steen\} and Merc{\`e} Boada and Lutz Fr{\"o}lich and Milica Kramberger and Nikolaos Scarmeas and Everard Vijverberg and Visser, \{Pieter Jelle\} and Gunhild Waldemar and Eric Westman and Henrik Zetterberg and Sebastiaan Engelborghs and Frank Jessen",

year = "2026",

month = aug,

day = "1",

doi = "10.1016/j.tjpad.2026.100598",

language = "English",

volume = "13",

journal = "Journal of Prevention of Alzheimer's Disease",

issn = "2274-5807",

publisher = "Springer International Publishing AG",

number = "7",

}

Frederiksen, KS, Boada, M, Frölich, L, Kramberger, M, Scarmeas, N, Vijverberg, E , Visser, PJ, Waldemar, G, Westman, E, Zetterberg, H, Engelborghs, S & Jessen, F 2026, 'Class-level aggregation obscures clinically relevant heterogeneity in anti-amyloid antibody trials: comments on a Cochrane review by individual members of the EADC', Journal of Prevention of Alzheimer's Disease, vol. 13, no. 7, 100598. https://doi.org/10.1016/j.tjpad.2026.100598

Class-level aggregation obscures clinically relevant heterogeneity in anti-amyloid antibody trials: comments on a Cochrane review by individual members of the EADC. / Frederiksen, Kristian Steen; Boada, Mercè; Frölich, Lutz et al.
In: Journal of Prevention of Alzheimer's Disease, Vol. 13, No. 7, 100598, 01.08.2026.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Class-level aggregation obscures clinically relevant heterogeneity in anti-amyloid antibody trials

T2 - comments on a Cochrane review by individual members of the EADC

AU - Frederiksen, Kristian Steen

AU - Boada, Mercè

AU - Frölich, Lutz

AU - Kramberger, Milica

AU - Scarmeas, Nikolaos

AU - Vijverberg, Everard

AU - Visser, Pieter Jelle

AU - Waldemar, Gunhild

AU - Westman, Eric

AU - Zetterberg, Henrik

AU - Engelborghs, Sebastiaan

AU - Jessen, Frank

PY - 2026/8/1

Y1 - 2026/8/1

KW - Alzheimer's disease

KW - Anti-amyloid

KW - Monocloncal antibodies

UR - https://www.scopus.com/pages/publications/105039015654

U2 - 10.1016/j.tjpad.2026.100598

DO - 10.1016/j.tjpad.2026.100598

M3 - Article

C2 - 42150345

SN - 2274-5807

VL - 13

JO - Journal of Prevention of Alzheimer's Disease

JF - Journal of Prevention of Alzheimer's Disease

IS - 7

M1 - 100598

ER -

Class-level aggregation obscures clinically relevant heterogeneity in anti-amyloid antibody trials: comments on a Cochrane review by individual members of the EADC

Keywords

Access to Document

Other files and links

Cite this